Retatrutide Prescribed Online to Ohio Residents

Medical Weight Loss Treatment in Ohio

Retatrutide (LY3437943) is a 39-amino acid synthetic peptide and triple receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Currently in Phase 3 clinical trials (TRIUMPH program), it produced 24.2% average weight loss at 48 weeks in Phase 2 data — the highest weight reduction observed in any peptide trial to date. Listed by OmniRx for research-use only (RUO).

Key Benefits

Triple receptor mechanism: GLP-1 + GIP + glucagon for amplified metabolic effect
Phase 2 data shows 24.2% average weight loss at 48 weeks (12mg dose)
~58% hepatic fat reduction in Phase 2 sub-group analyses
Elevated basal metabolic rate via glucagon receptor agonism
Research-grade purity ≥98% with full CoA, HPLC, and MS documentation

Who is a Good Candidate?

Intended for laboratory researchers and pre-clinical study investigators studying triple receptor agonism, obesity mechanisms, hepatic metabolism, or GLP/GIP/glucagon signaling pathways. Listed for research-use only (RUO) — not for human therapeutic use.

Available for research use

Serving Ohio

Ohio is the heart of it all—manufacturing and medicine, agriculture and innovation, world-class cities and charming small towns. OmniRx Health serves every Buckeye. From the corporate corridors of Columbus to the medical excellence of Cleveland, the cultural richness of Cincinnati to the college towns and farming communities throughout, our telehealth platform fits your Ohio lifestyle. Get expert care without fighting I-71 traffic or waiting weeks for an appointment.

Our providers are licensed by the State Medical Board of Ohio for comprehensive telehealth services statewide.

Ohio's extensive pharmacy network in Columbus, Cleveland, Cincinnati, and throughout the state ensures rapid prescription access.

Ohio has telehealth laws that support virtual care delivery while ensuring patient safety and provider accountability.

Ohio requires telehealth coverage parity for commercial insurers and has expanded Medicaid virtual care coverage.

Frequently Asked Questions

What is retatrutide and how does it work?: Retatrutide (CAS 2381089-83-2) is a 39-amino acid synthetic peptide that simultaneously activates GLP-1, GIP, and glucagon receptors. This triple agonism produces coordinated appetite suppression (GLP-1), amplified insulin and fat-cell metabolism (GIP), and increased hepatic glucose output and resting energy expenditure (glucagon). It is currently in Phase 3 clinical trials and is available for research-use only (RUO).
How does retatrutide compare to semaglutide and tirzepatide in research?: Phase 2 data (NEJM, 2023) showed retatrutide at 12mg produced 24.2% average weight loss at 48 weeks, outperforming semaglutide (~15% at 68 weeks) and tirzepatide (~22% at 72 weeks) in their respective trials. Retatrutide adds glucagon receptor agonism — absent in both comparators — which appears to drive additional metabolic rate elevation and hepatic fat clearance.
Is retatrutide available for human use?: No. Retatrutide has not received FDA approval for any human therapeutic use. It is currently in Phase 3 (TRIUMPH) clinical trials and is listed by OmniRx strictly as a research-use only (RUO) compound for laboratory and pre-clinical research applications.
Is telehealth legal in Ohio?: Yes, telehealth is fully legal in Ohio. The state supports virtual healthcare delivery, allowing licensed providers to offer consultations, prescriptions, and ongoing care.
Can Ohioans in all three C's cities use telehealth?: Absolutely. Whether you're in Columbus, Cleveland, or Cincinnati, telehealth provides convenient access to care without the urban traffic and parking challenges.
Does Ohio Medicaid cover telehealth?: Yes, Ohio Medicaid covers telehealth services for eligible members. The state has expanded virtual care coverage to improve healthcare access.